Accelerating precision medicine of cancer with SomaScan® proteomics
Accelerating precision medicine of cancer
with SomaScan proteomics
Proteomics has emerged as the next frontier in precision medicine, and several innovative proteomics platforms have been developed to drive biomarker discovery. We [at Beth Israel Deaconess Medical Center] are using the currently most comprehensive proteomics technology — the SomaScan Platform, which measures 7,000 proteins — to discover and independently validate diagnostic, predictive, and prognostic biomarkers for various cancers.
Efforts are especially focused on non-invasive biomarkers in serum, plasma, urine, and exosomes for a broad range of clinically highly relevant and challenging indications. Protein biomarker efforts for early detection of liver cancer and for predicting response to immunotherapy in metastatic melanoma will also be presented.
Learn about:
- Plasma protein biomarkers for predicting response to immunotherapy in metastatic melanoma
- Serum protein biomarkers for differential diagnosis of oral squamous cell carcinoma
- Plasma protein biomarkers for pancreatic cancer
- Exosome protein biomarkers for pancreatic cancer
- Urine protein biomarkers for pancreatic cancer and triple negative breast cancer
- Pre-diagnostic plasma protein biomarkers for early detection of hepatocellular cancer
Towia Libermann, PhD
Towia Libermann, PhD, is Associate Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center. He is also the Director of the Beth Israel Deaconess Medical Center Genomics, Proteomics, Bioinformatics and Systems Biology Center and of the Dana Farber/Harvard Cancer Center Cancer Proteomics Core.
Accelerating precision medicine of cancer with SomaScan proteomics
A presentation by Towia Libermann, PhD
More webinars
WebinarIdentifying Biomarkers for IBD Diagnosis and Management
In this webinar, you’ll hear how proteomics technology can enhance the identification of biomarkers for the accurate diagnosis of Crohn’s disease and ulcerative colitis, as well as the identification of biomarkers that predict response to TNF inhibitors and other biologics in patients with IBD.
WebinarBoutique Webinar : Predicting Pregnancy Complications with High-Plex Proteomics
The interdisciplinary team, comprising 10-15 scientists and clinician-scientists, is dedicated to advancing diagnostics and therapeutics aimed at enhancing maternal and fetal care. Their primary focus lies in the development of interventions for conditions such as ectopic pregnancy and preeclampsia, alongside the creation of diagnostics to prevent stillbirth.
WebinarYoung blood for old brains and the quest to slow brain aging
Aging leads to the degradation of function in nearly all tissues and organs. This process is marked by significant shifts in gene expression and changes in concentrations of all types of biological molecules. Recent technological progress has allowed biologists to measure an unprecedented number of these molecules throughout an organism